Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The ECOG-ACRIN E2108 trial

Seema Khan puts the results of the phase 3 ECOG-ACRIN E2108 trial of locoregional therapy for de novo stage IV breast cancer in context of the two other studies that addressed the same research question (5:38).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript
Image Credits